Lausanne, Switzerland

Aleva Neurotherapeutics

USPTO Granted Patents = 15

% Expired Patents = 6.7

Forward Citations = 139

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Andre Mercanzini (12 out of 20 patents)

silverMedal Alain Jordan (10 out of 17 patents)

bronzeMedal Alain Dransart (8 out of 8 patents)

4.  Marc Boers (7 out of 9 patents)

5.  Alexandre Michalis (7 out of 10 patents)

6.  Zbynek Struzka (4 out of 4 patents)

7.  Jason Jinyu Ruan (4 out of 4 patents)

8.  Pascal Harbi (3 out of 3 patents)

9.  André Mercanzini (3 out of 11 patents)

10.  Ingo Hartig (2 out of 2 patents)

11.  Khoa Nguyen (1 out of 2 patents)


15 patents:

Company Overview
Aleva Neurotherapeutics is a pioneering company based in Lausanne, Switzerland, specializing in advanced neurostimulation technologies. The organization focuses on developing innovative solutions for neurological disorders, utilizing cutting-edge research in neuroengineering and biomedicine. Aleva's expertise lies in creating targeted therapies that aim to improve patient outcomes through precise modulation of neural circuits, positioning the company at the forefront of the medical device industry in the realm of neuromodulation.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Aleva Neurotherapeutics USPTO Patent Assignee Logo
15 Patents

#24 in Lausanne

#805 in Switzerland

#39,959 in the World

Lausanne, CH
Lausanne, Switzerland
Forward Citations = 139

11 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aleva Neurotherapeutics. Retrieved from https://idiyas.com/company/aleva-neurotherapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…